P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YRS OF ADJ TAMOXIF

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 初步研究表明，如果在服用他莫昔芬五年后服用来曲唑，癌症复发可能会减少。这项研究的目的是了解停止他莫昔芬后接受来曲唑治疗或不接受进一步治疗的效果。第二个目的是确定治疗如何影响生活质量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preliminary research suggests cancer recurring may be reduced if letrozole is taken after five years of tamoxifen. The purpose of this study is to find out whether it is better to receive letrozole or no further treatment after stopping tamoxifen. The second purpose is to determine how the treatment affects the quality of life.